# epcoritamab

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/epcoritamab
Canonical HTML page: https://getyourbrief.com/entity/epcoritamab

## Timeline

- **2026-07-23**: Clarification on US Primary Endpoint — Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
- **2026-07-23**: Clarification on US Primary Endpoint — Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
- **2026-06-12**: EHA 2026 Presentation — Additional study results presented at the European Hematology Association Congress.
- **2026-06-12**: EHA 2026 Presentation — Additional study results presented at the European Hematology Association Congress.
- **2026-01-16**: Topline Results Announced — Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.
- **2026-01-16**: Topline Results Announced — Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.

## Recent coverage (4 stories, network-wide)

### Epcoritamab Trial Misses Survival Goal—What It Means for DLBCL Patients
2026-08-01 11:31:34 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 2

For healthcare providers treating relapsed/refractory DLBCL, the failure of epcoritamab to improve overall survival in a Phase 3 confirmatory trial raises critical questions about its long-term benefit over chemoimmunotherapy, even though the drug is already available under accelerated approval.
Full story: https://gethealthbrief.com/story/epcoritamab-survival-miss-dlbcl-patient-care

### Epcoritamab Phase 3 OS Miss Clouds $300M Revenue Stream for AbbVie and Genmab
2026-08-01 11:31:26 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2

The Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its US overall survival endpoint, jeopardizing full approval and the drug's growing $300 million annual sales. This clarification deepens the competitive threat from other bispecifics with survival data.
Full story: https://getbiobrief.com/story/epcoritamab-phase3-os-miss-revenue-risk

### Phase 3: Epcoritamab Combo Cuts DLBCL Progression Risk by 60%
2026-07-11 23:08:35 · Sector: health · Sentiment: Strongly positive · Impact: 8/10 · Sources: 3

A fixed-duration bispecific antibody plus lenalidomide dramatically improved progression-free survival over standard salvage chemoimmunotherapy in relapsed/refractory DLBCL, potentially offering healthcare systems a more effective and less toxic outpatient option while reshaping treatment guidelines and resource utilization.
Full story: https://gethealthbrief.com/story/epcoritamab-lenalidomide-phase3-dlbcl-60-percent-risk-reduction-health

### Epcoritamab-Lenalidomide Hits Phase 3 PFS Goals: 60% Risk Reduction
2026-07-11 23:08:27 · Sector: bio · Sentiment: Strongly positive · Impact: 8/10 · Sources: 3

AbbVie and Genmab's bispecific antibody epcoritamab combined with lenalidomide delivered a hazard ratio of 0.40 in a pivotal DLBCL trial, setting the stage for regulatory filings and a potential second-line market expansion that could challenge CAR-T dominance and redefine the bispecific landscape.
Full story: https://getbiobrief.com/story/epcoritamab-lenalidomide-phase3-dlbcl-biotech-abbv-gmab

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.